Massimo Cristofanilli
Northwestern University
CA15-3CancerSurgeryPathologyOncologyMetastatic breast cancerChemotherapyMetastasisDiseasePalbociclibFulvestrantInflammatory breast cancerCancer researchBreast cancerClinical trialCancer stem cellCirculating tumor cellMedicineBiomarker (medicine)Biology
759Publications
78H-index
32kCitations
Publications 758
Newest
#1Angela DeMichele (UPenn: University of Pennsylvania)H-Index: 56
#2Massimo Cristofanilli (NU: Northwestern University)H-Index: 78
Last. Richard S. Finn (UCLA: University of California, Los Angeles)H-Index: 64
view all 11 authors...
BACKGROUND Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC) treated in routine clinical practice in the USA. PATIENTS AND METHODS This was a retrospective observatio...
Source
#1Saya Jacob (NU: Northwestern University)H-Index: 3
#2Andrew A. Davis (WashU: Washington University in St. Louis)
Last. Massimo Cristofanilli (NU: Northwestern University)H-Index: 78
view all 15 authors...
Source
#1Ben O'Leary (ICR: Institute of Cancer Research)H-Index: 10
#2Rosalind J. Cutts (ICR: Institute of Cancer Research)H-Index: 15
Last. Nicholas C. Turner (ICR: Institute of Cancer Research)H-Index: 55
view all 12 authors...
BACKGROUND There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor DNA (ctDNA) can identify patients at higher risk of early progression on fulvestrant therapy with or without palbociclib, a CDK4/6i. METHODS PALOMA-3 was a phase III, multicenter, double-blind randomized controlled trial of palbociclib plus fulvestrant (n = 347) vs placebo plus f...
5 CitationsSource
#1Paolo D'AmicoH-Index: 6
#2Lorenzo GerratanaH-Index: 16
Last. Massimo CristofanilliH-Index: 78
view all 12 authors...
Source
#1Qiang ZhangH-Index: 18
#2Paolo D'AmicoH-Index: 6
Last. Massimo CristofanilliH-Index: 78
view all 18 authors...
Source
#1Saya JacobH-Index: 3
#2Andrew DavisH-Index: 3
Last. Massimo CristofanilliH-Index: 78
view all 16 authors...
Source
#1Ami N. Shah (NU: Northwestern University)H-Index: 10
#2Andrew A. Davis (NU: Northwestern University)H-Index: 32
Last. Massimo Cristofanilli (NU: Northwestern University)H-Index: 78
view all 15 authors...
Introduction: Previously reported data from our group and others have demonstrated an increase in genomic complexity and number of alterations over the course of treatment in MBC. Our study aims to categorize the pathogenicity of genomic aberrations found on serial ctDNA evaluations in MBC to explore the relevance of emerging mutations. Methods: Patients with MBC and ctDNA next-generation sequencing (NGS) analysis by Guardant360 (Guardant Health, Redwood City, CA) completed from 2015 to 2019 wer...
Source
#1Wolfgang JanniH-Index: 52
#2Tracy C. YabH-Index: 14
Last. Minetta C. LiuH-Index: 27
view all 41 authors...
Background: Several studies suggest clinical utility of serial circulating tumor cell (CTC) enumeration as a means of assessing response status in metastatic breast cancer (MBC). The aim of this study is to conduct a comprehensive pooled analysis comprising globally available data to further define and explore the role of CTC enumeration as a tool for early treatment monitoring in patients with MBC with a focus on the predictive power in different breast cancer subtypes and clinical settings. Me...
Source
#1Philippe AftimosH-Index: 17
Last. Jessica A. SorrentinoH-Index: 12
view all 19 authors...
Source
#1Andrew A. DavisH-Index: 32
#2Michael C. BurnsH-Index: 8
Last. Massimo CristofanilliH-Index: 78
view all 16 authors...
Source
12345678910
Close Researchers